HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Silent coronary vasospastic disease — Clinical Guidelines

Overview

Silent coronary vasospastic disease, often referred to as vasospastic angina or Prinzmetal angina, involves transient coronary artery spasms causing myocardial ischemia without typical symptoms, complicating diagnosis and management within chronic coronary disease. 9

Diagnosis

Clinical suspicion: History of angina at rest, transient ST-segment elevation, and potential triggers like stress or certain medications. 9

Provocative testing: Invasive coronary angiography with ergonovine, methylergonovine, or acetylcholine to induce spasm; gold standard but underutilized due to lack of standardized protocols. 9

Non-invasive imaging: Stress echocardiography, coronary CT angiography, and other imaging modalities may support suspicion but are not definitive for diagnosis. 8

Management

Lifestyle modifications: Smoking cessation, dietary changes, stress management, and regular physical activity. 1 4

Medications:

- Antiplatelet therapy: Aspirin or clopidogrel to reduce thrombotic events. 1 - Calcium channel blockers: Verapamil or diltiazem as first-line agents to prevent coronary artery spasm. 9 - Beta-blockers: For reducing myocardial oxygen demand and managing arrhythmias. 5 - Statins: To manage lipid levels and reduce atherosclerosis progression. 1

Colchicine: Low-dose colchicine has shown reduced cardiovascular events in chronic coronary disease, though specific to vasospastic angina requires further study. 10

Special Populations

Elderly: Tailored lifestyle modifications and careful medication management due to polypharmacy and comorbidities. 4

Comorbidities: Management should integrate care for coexisting conditions like hypertension and reduced left ventricular function, emphasizing guideline-directed therapy. 1 6

Key Recommendations

Implement comprehensive risk assessment tools to refine medical decision-making and tailor treatment plans for patients with chronic coronary disease, including silent vasospastic angina. (Evidence: Strong 5 6)

Utilize provocative testing protocols under expert guidance to diagnose vasospastic angina, despite current underutilization due to lack of standardization. (Evidence: Moderate 9)

Incorporate low-dose colchicine into management strategies for reducing cardiovascular events in patients with chronic coronary disease, pending further specific evidence for vasospastic angina. (Evidence: Moderate 10)

References

1 Williams MS, Levine GN, Kalra D, Agarwala A, Baptiste D, Cigarroa JE et al.. 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. Journal of the American College of Cardiology 2025. link 2 Williams MS, Levine GN, Kalra D, Agarwala A, Baptiste D, Cigarroa JE et al.. 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. Circulation. Cardiovascular quality and outcomes 2025. link 3 Chang IC, Pellikka PA, Winchester DE. 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease: A Summary for JASE. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2024. link 4 Gami A, Everitt I, Blumenthal RS, Newby LK, Virani SS, Kohli P. Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines. The American journal of medicine 2024. link 5 Khorsandi M, Blumenthal RS, Blaha MJ, Kohli P. The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Clinical cardiology 2024. link 6 Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH et al.. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023. link 7 Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH et al.. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology 2023. link 8 Winchester DE, Maron DJ, Blankstein R, Chang IC, Kirtane AJ, Kwong RY et al.. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 2023. link 9 Picard F, Adjedj J, Collet JP, Van Belle E, Monsegu J, Karsenty B et al.. Pharmacological coronary spasm provocative testing in clinical practice: A French Coronary Atheroma and Interventional Cardiology Group (GACI) position paper. Archives of cardiovascular diseases 2023. link 10 Cohn JN. Low-dose colchicine reduced risk for cardiovascular events in chronic coronary disease. Annals of internal medicine 2021. link

Silent coronary vasospastic disease